MiMedx Group, Inc. — Form 10-Q Summary
Business Context and Reporting Period
MiMedx is a developer, manufacturer, and marketer of regenerative biomaterials and bioimplants, including amniotic tissue products EpiFix and AmnioFix and device products HydroFix and CollaFix. The filing covers the three and nine months ended September 30, 2012. The company operates in one Biomaterials business segment.
Key Financial Metrics
| Metric | Q3 2012 | Q3 2011 | Nine Months 2012 | Nine Months 2011 |
|---|---|---|---|---|
| Net sales | $7.954 million | $2.152 million | $16.544 million | $5.125 million |
| Gross profit | $6.529 million | $1.266 million | $13.045 million | $2.683 million |
| Gross margin | 82.1% | 58.8% | 78.8% | 52.4% |
| Loss from operations | $(3.635) million | $(1.652) million | $(4.384) million | $(7.325) million |
| Net loss | $(4.219) million | $(1.766) million | $(6.057) million | $(7.617) million |
| Adjusted EBITDA | $0.726 million | $(0.934) million | $1.963 million | $(4.675) million |
| Net loss per share | $(0.05) | $(0.02) | $(0.07) | $(0.11) |
Revenue growth was driven primarily by increased sales of EpiFix and AmnioFix, supported by expanded distributor activity and a newly developed direct sales force focused on government wound-care accounts. Cost of products sold declined to 17.9% of revenue in the quarter and 21.2% year to date, compared with 41.2% and 47.6%, respectively, in the prior-year periods.
Operating expenses remained substantial. Third-quarter selling, general and administrative expense increased to $6.206 million from $2.356 million, reflecting sales-force expansion, reimbursement support, information technology, commissions, incentive-program accruals, and share-based compensation. Research and development expense was $0.839 million in the quarter and $1.749 million year to date.
At September 30, 2012, cash and cash equivalents were $7.621 million, compared with $4.112 million at December 31, 2011. Total current assets were $16.140 million and total current liabilities were $10.548 million. Current liabilities included a $5.545 million earn-out liability payable in common stock and approximately $1.174 million owed under a related-party convertible line of credit.
Debt included a $1.300 million related-party convertible line of credit and $5.000 million of convertible senior secured promissory notes, both bearing 5% interest. The line of credit initially matured December 31, 2012, with an option to extend for one year upon payment of a $65,000 fee. The senior notes mature December 31, 2013 and may require an additional 5% interest payment if not repaid before December 31, 2012. The notes are secured by company intellectual property.
Operating cash flow was negative $2.461 million for the first nine months of 2012, an improvement from negative $5.009 million in the prior-year period. Investing cash flow was negative $0.402 million, primarily for equipment. Financing cash flow was positive $6.372 million, including approximately $5.926 million from warrant exercises and $0.885 million from stock-option exercises.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue increased approximately 270% and nine-month revenue increased approximately 223% year over year.
- Gross margins improved materially due to greater scale, product mix, and higher tissue-processing efficiency.
- Despite improved gross profit, quarterly net loss increased because of higher selling and administrative spending, a $1.798 million intangible-asset impairment, a $1.320 million fair-value increase in the earn-out liability, and higher financing expense.
- Nine-month net loss improved from $7.617 million to $6.057 million, and adjusted EBITDA improved from a loss of $4.675 million to positive $1.963 million.
- The company raised approximately $4.9 million through exercises of callable warrants and issued 7.857 million shares for warrant exercises during the nine months. It also issued 2.633 million shares to settle the 2011 Surgical Biologics earn-out and 893,267 shares plus approximately $177,000 in cash to settle acquisition-related convertible notes.
- The company recorded a $1.798 million impairment related to HydroFix licenses because product growth was slower than projected.
Guidance, Outlook, Risks, and Unusual Items
The filing does not provide formal revenue or earnings guidance. Management stated that revenue was continuing to increase, anticipated cash from operations and financing activities plus existing cash were expected to fund operating and planned investing needs and debt obligations for the next twelve months, and production efficiencies were expected to improve as newly hired tissue-processing personnel gained experience.
- Revenue and receivables are highly concentrated: two customers represented approximately 78% of third-quarter revenue, including one customer at 62%; one customer represented 59% of accounts receivable at September 30, 2012.
- The company remained loss-making and dependent on external financing and equity exercises despite positive adjusted EBITDA.
- Accounts receivable increased to $6.170 million from $1.892 million at year-end, while inventory increased to $1.802 million from $0.713 million, creating working-capital and collection risks.
- HydroFix and other intangible assets remain subject to impairment risk. The company planned its regular annual testing of other intangible assets at December 31, 2012.
- Outstanding securities included 12.643 million stock options and 3.242 million warrants at September 30, 2012; convertible debt and related-party financing also could create future share dilution.
- Contractual obligations totaled approximately $7.245 million, including debt, leases, employment agreements, consulting agreements, and royalty payments. The filing reported no legal proceedings and no off-balance-sheet arrangements.
- Management concluded that disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Whether the company can convert strong revenue growth and improved gross margins into sustained GAAP operating profitability and positive operating cash flow.
- The timing and terms of repayment or extension of the $1.300 million related-party line of credit and the $5.000 million senior secured notes.
- The collectability of concentrated accounts receivable and the sustainability of revenue from the two largest customers.
- Whether HydroFix or other intangible assets require additional impairment charges.
- The ultimate amount and share-based settlement of the $5.545 million Surgical Biologics earn-out liability.
- The potential dilution from outstanding options, warrants, convertible debt, earn-outs, and other equity-linked obligations.